Header cover image

Chinese (SSE) Pharma Industry Analysis

UpdatedJan 26, 2022
DataAggregated Company Financials
Companies200
  • 7D-9.1%
  • 3M0.4%
  • 1Y-12.1%
  • YTD-12.3%

Over the last 7 days, the Pharma industry has dropped 9.2%, driven by pullbacks in Changchun High & New Technology Industry (Group) and Jiangsu Hengrui Medicine of 28% and 7.3%, respectively. However, the industry is down 12% over the past year.

Industry Valuation and Performance

Has the Chinese Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPE
Thu, 27 Jan 2022CN„2.8tCN„721.5bCN„73.6b32.7x
Sat, 25 Dec 2021CN„3.1tCN„718.2bCN„73.2b36.2x
Mon, 22 Nov 2021CN„3.0tCN„716.8bCN„73.0b31x
Wed, 20 Oct 2021CN„2.9tCN„705.1bCN„73.5b30.5x
Fri, 17 Sep 2021CN„2.8tCN„702.8bCN„71.2b31.5x
Sun, 15 Aug 2021CN„3.0tCN„702.6bCN„71.1b30.4x
Thu, 10 Jun 2021CN„3.2tCN„680.8bCN„69.7b34x
Wed, 03 Mar 2021CN„3.0tCN„646.4bCN„64.7b32.2x
Sat, 05 Dec 2020CN„2.9tCN„635.4bCN„47.7b35.2x
Tue, 08 Sep 2020CN„3.3tCN„626.5bCN„45.7b43.1x
Mon, 01 Jun 2020CN„2.5tCN„629.7bCN„43.4b39.2x
Thu, 05 Mar 2020CN„2.3tCN„644.0bCN„46.9b34.3x
Sun, 08 Dec 2019CN„2.1tCN„630.2bCN„57.4b28x
Sat, 31 Aug 2019CN„2.1tCN„621.0bCN„56.5b28.8x
Tue, 04 Jun 2019CN„1.9tCN„609.5bCN„58.0b30.1x
Fri, 08 Mar 2019CN„1.9tCN„594.7bCN„55.7b30.7x
PE Ratio

26.1x

Total Market Cap: CN„1.6tTotal Earnings: CN„55.7bTotal Revenue: CN„594.7b0%0%0%3 Year10 Year
202020212022

Current Industry PE: Investors are relatively neutral on the industry at the moment, considering it's trading close to its 3-year average PE ratio of 33.8x. It appears they believe that earnings will grow in-line with historical growth rates.

Past Earnings Growth: The earnings for companies in the Pharmaceuticals industry have grown 9.7% per year over the last three years, and revenues for these companies have grown 6.7% per year. This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Chinese Pharma industry?

Pharma-9.06%

Industry PE: Investors are most optimistic about the Pharma industry, which is trading close to its 3-year average PE ratio of 33.8x. This is likely because analysts are expecting annual earnings growth of 24%, which is higher than its past year's earnings growth of 15% per year.

Forecasted Growth: Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 24% over the next 5 years. This is better than it's past earnings growth rate of 15% per year.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
2001 Zhejiang NHUCN„31.783.2%
+CN„2.7b
-2.9%PE21.9x
300039 Shanghai Kaibao PharmaceuticalLtdCN„6.7114.7%
+CN„899.6m
58.3%PE60.6x
605507 Guobang PharmaCN„31.334.7%
+CN„793.5m
n/aPE25.2x
688166 BrightGene Bio-Medical TechnologyCN„33.502.9%
+CN„385.4m
-28.8%PE61x
300584 Nanjing Hicin PharmaceuticalCN„35.808.1%
+CN„320.4m
90.1%PE122.3x
Simply Wall Stℱ
Simply Wall Street Pty Ltd
17-21 Bellevue Street, Surry Hills, Sydney
Download on the App StoreGet it on Google Play
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News